Search

Displaying results 7951 - 7960 of 8573 in total
  1. Drug

    Cimetropium

    go.drugbank.com/drugs/DB09271
    Investigational

    It has never been approved for use in the U.S. or Canada.

  2. Drug

    Tasurgratinib

    go.drugbank.com/drugs/DB21222
    Investigational

    Tasurgratinib has a monoisotopic molecular weight of 587.27 Da.

  3. Drug

    Etranacogene dezaparvovec

    go.drugbank.com/drugs/DB16791
    ApprovedInvestigational

    [L45255] Etranacogene dezaparvovec was approved by the EMA in February 2023[L45439,L45444] and by Health Canada in October 2023.[L48801] … [L44156] Etranacogene dezaparvovec was approved by the FDA in November 2022 for the treatment of select patients with hemophilia B, becoming the first gene therapy approved for this indication.

  4. Drug

    Zebularine

    go.drugbank.com/drugs/DB03068
    Experimental

    It acts as a transition state analog inhibitor of cytidine deaminase by binding to the active site as covalent hydrates.

  5. Drug

    Zeranol

    go.drugbank.com/drugs/DB11478
    ExperimentalVet approved

    It is 3-4x more potent as an estrogen agonist than the related compound zearalenone. … It is a mycotoxin, derived from fungi in the Fusarium family, and may be found as a contaminant in fungus-infected crops.

  6. Drug

    Amylmetacresol

    go.drugbank.com/drugs/DB13908
    Approved

    Amylmetacresol is often combined with dichlorobenzyl alcohol and menthol in the commonly used sore throat lozenges, known as Strepsils [L2575].

  7. Drug

    Triphosphoric acid

    go.drugbank.com/drugs/DB03896
    Experimental

    Used as water softener, peptizing agent, emulsifier & dispersing agent; ingredient of cleansers; meat preservative.

  8. Drug

    XAV-19

    go.drugbank.com/drugs/DB15895
    Investigational

    As of July, 2020, the company is conducting a Phase 2 randomized clinical trial to define dosing safety and efficacy of XAV-19 (NCT04453384). … Xenothera has partnered with LFB, a pharmaceutical company, to develop XAV-19, and with Nantes University Hospital to test the treatment in patients[L16553,L16558].

  9. Drug

    ATG003

    go.drugbank.com/drugs/DB05069
    Investigational

    ATG003, a novel anti-angiogenic drug candidate and a formulation of mecamylamine, is currently in clinical development for neovascular age-related macular degeneration.

  10. Drug

    R450

    go.drugbank.com/drugs/DB05469
    Experimental

    R450 is an alpha 1 antagonist that acts to tighten the muscle tone in the bladder. It is being considered for treatment of stress-related urinary incontinence. Phase IIa data for the drug show it reduced the number of incontinent episode...